BRB

23andMe Complies with FDA Order

The popular genetic testing service known as 23andMe has agreed to comply with the FDA’s directive to "discontinue consumer access to its health-related genetic tests" until an investigation is complete. The company, which is backed by Google Ventures and Facebook billionaire Yuri Milner, promises to identify health risks for more than 250 diseases and health conditions. The $99 test sold by 23andMe came under fire after an open letter from the FDA revealed that no proof has been made public that the technology is actually real. In a statement to the public, co-founder and CEO Anne Wojcicki said she and her team plan to work with the FDA to prove the “validity of the science” behind it. In the interim, 23andMe will continue to offer its Personal Genome Service—including ancestry information and access to raw data without interpretation.